Combined targeted therapy and immunotherapy for cancer treatment
作者机构：Department of Hepatobiliary and Pancreatic SurgeryThe First Affiliated HospitalZhejiang University School of MedicineHangzhou 310003Zhejiang ProvinceChina
出 版 物：《World Journal of Clinical Cases》 (世界临床病例杂志)
年 卷 期：2021年第9卷第26期
页 面：7643-7652页
核心收录：
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金：The National Key Research and Development Program of China,No.2019YFC1316000 the National High Technology Research and Development Program of China,No.2015AA020405 the National Natural Science Foundation of China,No.81672337 China Postdoctoral Science Foundation,No.2020M671761
主 题：Cancer Targeted therapy Immunotherapy Combined treatment
摘 要：Although targeted therapies and immunotherapies have been effective againstseveral malignancies, the respective monotherapies are limited by low and/orshort-term responses. Specific inhibitors of oncogenic signaling pathways andtumor-associated angiogenesis can activate the anti-tumor immune responses byincreasing tumor antigen presentation or intratumor T cell infiltration. Additionalinsights into the effects and mechanisms of targeted therapies on the induction ofanti-tumor immunity will facilitate development of rational and effective combinationstrategies that synergize rapid tumor regression and durable response. Inthis review, we have summarized the recent combinations of targeted therapiesand immunotherapies, along with the associated clinical challenges.
维普期刊数据库